Enveric Biosciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ENVB research report →
Price Chart
About the company
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress.
- CEO
- Joseph Edward Tucker
- IPO
- 2015
- Employees
- 6
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on ENVB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $6.58M
- P/E
- -0.09
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.73
- EV/EBITDA
- 0.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -168.05%
- ROIC
- -107.99%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-200,858+40.5%
- Op Income
- $-8,774,448
- Net Income
- $-12,131,472-26.7%
- EPS
- $-36.24+84.1%
- OCF Growth
- -5.4%
- FCF Growth
- -5.4%
- 52W High
- $13.25
- 52W Low
- $1.17
- 50D MA
- $1.47
- 200D MA
- $2.29
- Beta
- 1.18
- RSI (14)
- 48
- Avg Volume
- 104.05K
No earnings-call transcripts are available for ENVB yet.
- Free Float
- 96.9%
- Shares Outstanding
- 4.48M
- Float Shares
- 4.34M
of shares held by institutions
11 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Sio Capital Management, LLC | 180.00K | ▲ 180.00K |
| Ikarian Capital, LLC | 100.00K | ▲ 100.00K |
| Advisorshares Investments LLC | 35.42K | ▲ 18.44K |
| Renaissance Technologies LLC | 32.06K | ▲ 32.06K |
| Armistice Capital, LLC | 32.00K | ▲ 32.00K |
| Boothbay Fund Management, LLC | 30.14K | ▲ 30.14K |
| Xtx Topco Ltd | 18.99K | ▲ 18.99K |
| Hrt Financial LP | 15.46K | ▲ 15.46K |
| Vanguard Capital Management LLC | 14.91K | ▲ 14.91K |
| Citadel Advisors LLC | 13.96K | ▲ 13.96K |
| Stonex Group Inc. | 11.81K | ▲ 11.81K |
| Geode Capital Management, LLC | 11.79K | ▼ 20.36K |
Held by 6 ETFs
Biggest fund positions in ENVB by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 23, 25 | DeWitt Sheila | other | 7,633 |
| Dec 23, 25 | Kegler George A. | other | 7,633 |
| Dec 23, 25 | PASQUALONE FRANK | other | 7,633 |
| Dec 23, 25 | Schabacker Marcus | other | 7,633 |
| Dec 23, 25 | Tucker Joseph Edward | other | 60,296 |
| Dec 23, 25 | WEBB MICHAEL D | other | 7,633 |
| Dec 23, 25 | Coveney Kevin Michael | other | 40,198 |
| May 8, 25 | Coveney Kevin Michael | other | 74,150 |
| May 8, 25 | Facchini Peter J. | other | 24,717 |
| May 8, 25 | Tucker Joseph Edward | other | 98,866 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ENVB coverage
Recent articles, reports, and earnings notes.
No research on ENVB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ENVB report →Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
businesswire.com · Sep 15
Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference
businesswire.com · Sep 1
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026
businesswire.com · Aug 14
Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Candidate
benzinga.com · Aug 5
Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003
businesswire.com · Aug 5
Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
businesswire.com · Jul 28
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
businesswire.com · Jun 29
Enveric Biosciences Announces Participation in 2026 BIO International Convention
gurufocus.com · Jun 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.